LIPO Stock Overview
A biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Lipella Pharmaceuticals Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.42 |
52 Week High | US$2.71 |
52 Week Low | US$0.36 |
Beta | 0 |
11 Month Change | -8.63% |
3 Month Change | -44.14% |
1 Year Change | -79.55% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -91.09% |
Recent News & Updates
Recent updates
Shareholder Returns
LIPO | US Biotechs | US Market | |
---|---|---|---|
7D | -18.7% | 2.7% | 4.0% |
1Y | -79.5% | 15.4% | 24.9% |
Return vs Industry: LIPO underperformed the US Biotechs industry which returned 12.6% over the past year.
Return vs Market: LIPO underperformed the US Market which returned 21.7% over the past year.
Price Volatility
LIPO volatility | |
---|---|
LIPO Average Weekly Movement | 37.2% |
Biotechs Industry Average Movement | 10.6% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.1% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: LIPO's share price has been volatile over the past 3 months.
Volatility Over Time: LIPO's weekly volatility has increased from 23% to 37% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | 6 | Jon Kaufman | www.lipella.com |
Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
Lipella Pharmaceuticals Inc. Fundamentals Summary
LIPO fundamental statistics | |
---|---|
Market cap | US$4.39m |
Earnings (TTM) | -US$4.14m |
Revenue (TTM) | US$507.20k |
8.3x
P/S Ratio-1.0x
P/E RatioIs LIPO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
LIPO income statement (TTM) | |
---|---|
Revenue | US$507.20k |
Cost of Revenue | US$3.04m |
Gross Profit | -US$2.53m |
Other Expenses | US$1.61m |
Earnings | -US$4.14m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.41 |
Gross Margin | -499.13% |
Net Profit Margin | -816.71% |
Debt/Equity Ratio | 0% |
How did LIPO perform over the long term?
See historical performance and comparison